Recent Updates
Recently added Catalysts

ERAS-0015

Phase 1

Metastatic Solid Tumors | Small molecule | Oncology |Erasca, Inc.|Last Updated: Sep 11, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
CONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment200
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06983743A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid TumorsPHASE1 RECRUITING 200 — — Jun 5, 2025Dec 1, 2028Sep 11, 20255 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Dose Limiting Toxicities (DLT)
Study Day 1 up to Day 21

Based on toxicities observed

Maximum tolerated dose (MTD)
Study Day 1 up to Day 21

Based on toxicities observed

Recommended dose for expansion (RDE)
Study Day 1 up to Day 21

Based on toxicities observed

Adverse Events
Study Day 1 up to Day 21

Incidence and severity of treatment-emergent AEs and serious AEs

Plasma concentration (Cmax)
Study Day 1 up to 65

Maximum plasma concentration of ERAS-0015

Time to achieve Cmax (Tmax)
Study Day 1 up to 65

Time to achieve maximum plasma concentration of ERAS-0015

Area under the curve
Study Day 1 up to 65

Area under the plasma concentration-time curve of ERAS-0015

Half-life
Study Day 1 up to 65

Half-life of ERAS-0015

Secondary Endpoints
Objective Response Rate (ORR)
Assessed up to 24 months from time of first dose
Duration of Response (DOR)
Assessed up to 24 months from time of first dose
Time to Response (TTR)
Assessed up to 24 months from time of first dose
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
ERAS-0015 Monotherapy Dose Optimization.EXPERIMENTALEscalating doses of ERAS-0015 administered orally.
ERAS-0015 Combination Dose OptimizationEXPERIMENTALERAS-0015 administered orally with another investigational agent.
Interventions
NameTypeDescription
ERAS-0015DRUGERAS-0015 Administered orally
ERAS-0015 in combinationDRUGERAS-0015 Administered orally and in combination with either Keytruda (pembrolizumab) via IV administration or Vectibix (panitumumab) via IV administration.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 99 Years
SexALL
Healthy VolunteersNo
Study Sites5

Inclusion Criteria: * Age ≥ 18 years * Willing and able to give written informed consent * Pathological documentation of tumor type and mutation prior to the first dose of study drug(s), for applicable cohorts. * There is no available standard systemic therapy available for the patient's tumor hist...

Countries:United States
Unlock Eligibility Criteria
Competitive Landscape -Other Solid Tumors 9 trials
CompanyTickerTrialsLead PhaseDrugs
Merck & Co., Inc.MRK2PHASE2pembrolizumab, V503, GARDASIL
Incyte CorporationINCY1PHASE2Chemotherapy, Retifanlimab
Novartis AG Sponsored ADRNVS1PHASE1KFA115, pembrolizumab
Iovance Biotherapeutics IncIOVA2PHASE2E7 TCR-T cells, Aldesleukin
AstraZeneca PLCAZN1 — Trastuzumab deruxtecan
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT06983743primaryCompletionDate: changed
LOWMay 24, 2026NCT06983743studyFirstPostDate: changed